Does rember stop Alzheimer’s?

The video contains an interview with Professor Claude Wischik, Chairman of TauRx Therapeutics. It is a good explanation of the drug rember, its targets, future development and the upcoming Phase 3 trial. Rember is being touted as a major breakthrough in the treatment of Alzheimer’s disease.

A major breakthrough in the treatment of Alzheimer’s disease was revealed by scientists at the Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2008). Their pioneering research points to a new treatment that appears to slow the progress of the disorder by 81% over a year, and could offer hope to millions worldwide. The product – remberTM – is the first drug to act on the tangles associated with alzheimer’s, dementia and other memory disorders.

TauRx Therapeutics is developing a novel treatment based on an entirely new approach which targets the tangles, aggregates of abnormal fibres of tau protein forming inside nerve cells in the brain. These aggregates first destroy nerve cells critical for memory and then destroy neurons in other parts of the brain as the disease progresses.

Patients receiving the study treatment experienced an 81% reduction in cognitive decline over one year, and did not experience a significant decline in their mental function over 19 months. The TauRx brain imaging data also showed that the drug had its biggest effect in the memory critical parts of the brain where the tangle density is highest.

Professor Claude Wischik, Chairman of TauRx Therapeutics and Professor of Psychiatric Geratology and Old Age Psychiatry at the University of Aberdeen’s Institute of Medical Sciences, who led the research, said: “This is an unprecedented result in the treatment of Alzheimer’s disease. We have demonstrated for the first time that it may possible to arrest the progression of this disease by targeting the tangles which are highly correlated with the disease.”

“This is the most significant development in the treatment of the tangles since Alois Alzheimer discovered them in 1907.”

 

Does rember stop Alzheimer’s?

The video contains an interview with Professor Claude Wischik, Chairman of TauRx Therapeutics. It is a good explanation of the drug rember, its targets, future development and the upcoming Phase 3 trial. Rember is being touted as a major breakthrough in the treatment of Alzheimer’s disease.

A major breakthrough in the treatment of Alzheimer’s disease was revealed by scientists at the Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2008). Their pioneering research points to a new treatment that appears to slow the progress of the disorder by 81% over a year, and could offer hope to millions worldwide. The product – remberTM – is the first drug to act on the tangles associated with alzheimer’s, dementia and other memory disorders.

TauRx Therapeutics is developing a novel treatment based on an entirely new approach which targets the tangles, aggregates of abnormal fibres of tau protein forming inside nerve cells in the brain. These aggregates first destroy nerve cells critical for memory and then destroy neurons in other parts of the brain as the disease progresses.

Patients receiving the study treatment experienced an 81% reduction in cognitive decline over one year, and did not experience a significant decline in their mental function over 19 months. The TauRx brain imaging data also showed that the drug had its biggest effect in the memory critical parts of the brain where the tangle density is highest.

Professor Claude Wischik, Chairman of TauRx Therapeutics and Professor of Psychiatric Geratology and Old Age Psychiatry at the University of Aberdeen’s Institute of Medical Sciences, who led the research, said: “This is an unprecedented result in the treatment of Alzheimer’s disease. We have demonstrated for the first time that it may possible to arrest the progression of this disease by targeting the tangles which are highly correlated with the disease.”

“This is the most significant development in the treatment of the tangles since Alois Alzheimer discovered them in 1907.”

 

rember and TauRx Therapeutics

I am getting emails asking me about rember. People want to know more about the drug and the phase 3 clinical trial. They are also asking how they can contact the company direct.

To learn more about the drug and get answers to your question use this link:

FAQ (Frequently Asked Questions) about TauRx Therapeutics and rember™

To contact the company use this link:

TauRx Therapeutics Ltd & University of Aberdeen – New treatment halts progress of Alzheimer’s disease

 

FAQ (Frequently Asked Questions ) about TauRx Therapeutics and rember™

There is a lot of buzz right now about rember. People want to know more about rember, how it works, and when it might become available. We answer these frequently asked questions on the next page.

New research findings point to a new treatment that appears to slow the progress of Alzheimer’s by 81% over a year. The product – remberTM – is the first drug to act to arrest the progression of Alzheimer’s disease by targeting the tangles which are highly correlated with the disease.

What is rember and how is it supposed to work?

rember is a new version of an existing chemical substance, but modified especially to be used as a drug for the treatment and prevention of Alzheimer’s. The chemical, called MTC, has been used in the past to treat urinary tract infections and other conditions.

TauRx Therapeutics Ltd have claimed that rember acts by ‘disrupting and dissolving’ the abnormal build-up of Tau protein in brain cells, thus breaking down (and possibly preventing) tangles.

How is rember different from existing drugs for Alzheimer’s disease?

Existing drugs for Alzheimer’s disease, such as Aricept, work to lessen the symptoms of the illness. These drugs prevent the breakdown of acetylcholine, a chemical which carries messages between brain cells. This means that there is more acetylcholine available to transmit messages. This may temporarily improve or stabilise the symptoms of the disease. However, these drugs do nothing to stop the death of the nerve cells in the long run, so they will not bring a permanent cure.

It is claimed that rember could prevent the death of nerve cells.
Is rember a cure for Alzheimer’s Disease?

While very promising results have been given following the Phase 2 trial of rember, it is important to consider the following details:

* these results are from a trial of 321 people, from Aberdeen, Birmingham and Singapore, over a period of less than 2 years;

* a Phase 3 trial, with far more particpants and on a global scale, must now take place and its results will ultimately determine the success of the treatment;

* the findings of the Phase 2 trial are yet to be published in an academic journal, which would allow other scientists to replicate the testing in order to see if the same results occured;

* potential side-effects (especially after long-term use) and varying individual reponses to the treatment could take many more years, perhaps decades, to determine.

Results so far are promising, but we must wait until the end of the testing phase (which could take between 3-4 years) before we truly know how effective rember is.

Will rember work for other types of dementia?

As far as we are aware, rember has only been designed for, and tested on, Alzheimer’s disease. However, TauRx says that they hope rember may also help in Parkinson’s disease, as similar protein fibres similar to tau protein (synuclein fibres) are found in the brain cells of people with Parkinson’s disease. They are planning a separate trial to see if it is effective.

Can I get rember from my family physician?

rember is still at trial stage and TauRx Therapeutics Ltd have stated that any licensing of the drug is unlikely prior to 2012.

Can I buy rember over the internet?

It can be extremely dangerous to buy any drug over the internet or from other sources. rember is still being developed and tested: this potential treatment for Alzheimer’s disease cannot be purchased online.

How can I get involved in the rember Phase 3 trial?

Right now the Phase 3 clinical trial has not been scheduled. We will continue to monitor the situation at the Alzheimer’s Reading Room and keep you posted.

When will rember be available on prescription?

If the trials are successful and the drug is licensed, the earliest it is likely to be available is 2012.

TauRx Therapeutics Ltd & University of Aberdeen – New treatment halts progress of Alzheimer’s disease

Amazon.com Widgets

 

Tau drug shows early promise in Alzheimer’s

clipped from www.healthcentral.com An Alzheimer’s drug that attacks abnormal tangles in the brain appeared to slow progression of the disease, British researchers said on Tuesday, but doctors cautioned that the results are early. The drug, made by private biotechnology company TauRX and called Rember, produced a significant improvement in key measures of thinking and memory in people with moderate Alzheimer’s disease, company officials said. The drug is among the first to attack tangles of tau protein in the brain that are strongly associated with dementia in Alzheimer’s disease. “We’ve demonstrated for the first time we can halt the disease by a treatment that aims to dissolve the tangles,” said Claude Wischik of the University of Aberdeen and chairman of TauRX Therapeutics in Singapore. The researchers tested 321 patients with mild to moderate Alzheimer’s disease at 17 centers in the United Kingdom and Singapore, they told the International Conference on Alzheimer’s disease in Chicago.